Review article · 2020 · Open access

Drug Therapy in Obesity: A Review of Current and Emerging Treatments

David M. Williams, Asif Nawaz, Marc Evans

Diabetes Therapy, 11(6), 1199–1216 · Published 15 April 2020 · DOI 10.1007/s13300-020-00816-y

Open PDFView at the publisherCite this paper

In brief

“Drug Therapy in Obesity: A Review of Current and Emerging Treatments” is a 2020 review article by David M. Williams and 2 co-authors, published in Diabetes Therapy. OpenAlex counts 232 citations as of 21 November 2026, which puts it in the top 1% of works published in 2020 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Diabetes Therapy.

Citations
232
Most cited in
2023 (48)
Field-weighted impact
3.87
References
97
Authors
3

Abstract

Whilst the prevalence of obesity continues to increase at an alarming rate worldwide, the personal and economic burden of obesity-related complications becomes ever more important. Whilst dietary and lifestyle measures remain the fundamental focus of the patient to counter obesity, more frequently pharmacological and/or surgical interventions are required. Nevertheless, these therapies are often limited by weight loss efficacy, side effects, surgical risks and frequently obesity relapse. Currently, only five drug therapies are approved for the specific treatment of obesity. However, our understanding of the pathophysiology of obesity and of gut hormones has developed precipitously over the last 20-30 years. As a result, there has been a recent movement to create and use analogues that manipulate these gut hormones to support weight loss. In this article we review the efficacy of the currently approved drug therapies and discuss future potential drug mechanisms and early clinical trial results exploring these budding avenues. We discuss the use of glucagon-like peptide-1 (GLP-1) analogues as monotherapy and unimolecular dual or triple agonists that exploit the GLP-1 receptor and/or the gastric inhibitory peptide (GIP) receptor and/or the glucagon receptor. We also explore the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, amylin mimetics, leptin analogues, ghrelin antagonists and centrally acting agents to suppress appetite [neuropeptide Y (NPY) antagonists, melanocortin-4 receptor (MC4R) agonists and cannabinoid-1 receptor antagonists]. Whilst further evidence is required to support their clinical use, preclinical and early clinical trial results are encouraging.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Williams, D. M., Nawaz, A., & Evans, M. (2020). Drug Therapy in Obesity: A Review of Current and Emerging Treatments. Diabetes Therapy, 11(6), 1199–1216. https://doi.org/10.1007/s13300-020-00816-y

MLA 9

Williams, David M., et al. “Drug Therapy in Obesity: A Review of Current and Emerging Treatments.” Diabetes Therapy, vol. 11, no. 6, 2020, pp. 1199–1216. https://doi.org/10.1007/s13300-020-00816-y.

Chicago

Williams, David M., Asif Nawaz, and Marc Evans. 2020. “Drug Therapy in Obesity: A Review of Current and Emerging Treatments.” Diabetes Therapy 11 (6): 1199–1216. https://doi.org/10.1007/s13300-020-00816-y.

Harvard

Williams, D. M., Nawaz, A. and Evans, M. (2020) ‘Drug Therapy in Obesity: A Review of Current and Emerging Treatments’, Diabetes Therapy, 11(6), pp. 1199–1216. doi:10.1007/s13300-020-00816-y.

IEEE

D. M. Williams, A. Nawaz, and M. Evans, “Drug Therapy in Obesity: A Review of Current and Emerging Treatments,” Diabetes Therapy, vol. 11, no. 6, pp. 1199–1216, 2020, doi: 10.1007/s13300-020-00816-y.

BibTeX

@article{williams2020drug,
  title     = {{Drug Therapy in Obesity: A Review of Current and Emerging Treatments}},
  author    = {Williams, David M. and Nawaz, Asif and Evans, Marc},
  journal   = {Diabetes Therapy},
  year      = {2020},
  volume    = {11},
  number    = {6},
  pages     = {1199--1216},
  doi       = {10.1007/s13300-020-00816-y},
  url       = {https://doi.org/10.1007/s13300-020-00816-y}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20201414
20214444
20223838
20234848
20243434
20252929
20262525

Its field-weighted citation impact is 3.87: it has been cited 3.87 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment

  • anti-obesity drugs
  • GLP-1 receptor agonists
  • glucagon receptor
  • SGLT2 inhibitors
  • amylin analogues
  • ghrelin antagonist
  • melanocortin-4 receptor agonist
  • cannabinoid-1 receptor antagonist

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Williams, D. M., Nawaz, A., & Evans, M. (2020). Drug Therapy in Obesity: A Review of Current and Emerging Treatments. Diabetes Therapy, 11(6), 1199–1216. https://doi.org/10.1007/s13300-020-00816-y

How many times has this paper been cited?

232 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Diabetes Therapy: sign in and open the PDF from this page.

Who wrote this paper?

David M. Williams, Asif Nawaz, Marc Evans.

What is the DOI of this paper?

10.1007/s13300-020-00816-y, permanently at https://doi.org/10.1007/s13300-020-00816-y. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.